From Volume to Value

A Structural Shift in Pharmaceutical Innovation

The pharmaceutical industry is in the middle of a genuine structural transition with a fundamental rethinking of where value comes from and who creates it.

For most of the twentieth century, the dominant logic was straightforward: develop a drug for a large patient population, drive volume through a broad sales force, and protect margins until the patent cliff. When exclusivity expired, generics players like Teva and Viatris would absorb the asset and compete on price. Big Pharma moved on to the next blockbuster. The model was capital-intensive, repeatable, and for a long time, enormously profitable.

That model has not disappeared, but it is no longer the frontier. Over the past decade, the most dynamic and financially significant part of the industry has become specialty pharmaceuticals; a segment defined by therapies that treat complex, chronic, or rare diseases, often requiring highly individualised patient management. These medicines serve smaller populations, but command prices that reflect high unmet need, therapeutic complexity, and limited alternatives.

The commercial logic is inverted: fewer patients, higher value per patient, and a completely different operating model. Understanding this is essential to navigating a shifting era of pharmaceutical innovation.

What Makes Specialty Pharma Different

The differences between specialty and traditional pharma run deeper than price points. In traditional markets (e.g., large oncology, hypertension, diabetes), commercial success depends on reach. Large sales forces call on thousands of practitioners, formulary placement matters enormously, and switching costs are low. Competition is fought largely on price, marketing, and familiarity.

Specialty pharma operates differently. Prescribing decisions for niche oncology indications, critical care, and rare diseases are typically concentrated among a small number of specialist physicians at dedicated treatment centres. An experienced and knowledgeable medical affairs team engaging the right clinicians can be more impactful to inform clinical decision-making than promoting a product via a mass sales force. Relationships with those genuinely driving clinical practice carry real weight, not as a nominal strategy, but as a commercial necessity.

Patient advocacy and support are other defining characteristics. For many specialty therapies, the treatment journey is complicated: diagnosis is often non-standard, monitoring requirements are intensive, and reimbursement pathways are rarely straightforward. Companies typically build integrated support programs covering physician and patient education, reimbursement navigation, adherence monitoring, and, in some cases, home care coordination. In addition to delivering value for patients, these programs reduce abandonment rates, generate real-world data, and strengthen the case with payers; but they represent a genuine operational investment that traditional pharma rarely needed to make.

Finally, pricing reflects a different equation entirely. The price of a specialty therapy is not benchmarked like a mass-market competitor; it is negotiated based on clinical value, unmet need and, increasingly, health technology assessments that tie reimbursement to demonstrated outcomes. This creates real pricing power, but also real political and reputational exposure. Specialty drugs routinely top the lists of the most expensive therapies, and payer scrutiny of these therapies is only intensifying. It is important to bear in mind that these therapies are often treating diseases where the number of patients is 10s or 100s; rarely 1,000s.

The Forces Behind the Shift

Three converging dynamics have driven the expansion of specialty pharma.

The first is scientific. Advances in proteomics, genomics, and manufacturing have made it possible to develop highly targeted therapies for diseases once considered untreatable. Regulators have moved with this. The FDA has expanded the use of accelerated pathways, various designations, and closer sponsor collaboration to make development more attractive in high-unmet-need areas. This has meaningfully compressed timelines and increased approval rates. Roughly half of all new FDA drug approvals are now for orphan diseases.

This regulatory evolution is underappreciated as a structural enabler; without it, much of the scientific progress would have taken a decade longer to reach patients and not economically viable. The withdrawal of several accelerated approvals in recent years raises legitimate questions. Despite those debates, the broader regulatory direction remains supportive of specialty innovation

The second is organisational. A generation of professionals from regulatory affairs, market access, medical affairs, and commercial operations has migrated from large pharmaceutical companies into smaller biotech and specialty firms. Combined with outsourced operating models and digital infrastructure that reduce the fixed cost of launching, this has enabled lean organisations to execute sophisticated commercial strategies that once required the resources of a major corporation. Forty percent of new molecular entities launched between 2018 and 2023 came from first-time launchers; unimaginable twenty years ago.

The third is financial. Specialist life sciences capital including both venture and broader private equity (PE) have developed the patience and expertise to support specialty pharma through long development timelines and complex launches. Prior to 2022, a prolonged low-interest rate environment drove significant capital into illiquid assets; life sciences absorbed a meaningful share, reinforced by strong M&A and IPO exit markets. Whilst the downturn of the IPO market and the post-2022 capital tightening slowed deployment temporarily, 2025 and 2026 have begun to show the return to normality.

The Growing Role of Private Equity

One of the more significant and underappreciated developments in specialty pharma has been PE’s evolution from passive financial backer to active builder of commercialisation platforms. PE firms have approached the sector primarily through asset acquisition and roll-up platforms. The aim is to consolidate underutilised or non-core assets from large pharma, acquire regional players or take on upcoming launches from biotech and plug these into larger specialty-focused organisations. These platforms can achieve meaningful scale in commercialisation, manufacturing, and market access while maintaining a tight therapeutic focus.

There is a genuine case for PE's contribution here. It has unlocked value in assets that large pharma had deprioritised and created a more liquid market for non-core products. It has also helped sustain the specialist ecosystem; keeping experienced commercial professionals employed across successive platforms and giving both biotechs and VCs a credible buyer base beyond IPO for their later-stage assets.

The specialty model works when commercial expertise genuinely serves the asset by making it available to more of the patients would benefit from it. It fails when applied purely as financial leverage. Specialty pharma depends heavily on long-term relationships with clinicians, patients, and payers; when pricing or portfolio decisions become detached from those relationships, the damage extends beyond the individual company.

Investor expectations of a return within a narrow window demand seamless execution and that does not always sit comfortably alongside the long-term relationship-building that defines successful commercialisation. A platform optimised for an exit in the near term may invest in these capabilities differently than one with a longer horizon. As more industry professionals move into PE, horizon planning is becoming more realistic.

For Big Pharma, the dynamic cuts both ways. PE-backed platforms provide a useful mechanism for monetising non-core assets, and there is genuine value in a liquid buyer base for products that no longer fit a major company's strategic priorities. This model however is challenged as PE-backed platforms compete aggressively for the same high-value assets and niches, driving up acquisition valuations and intensifying competition across specialty segments.

Implications for the incumbent

The shift toward specialty pharma puts real pressure on large pharmaceutical companies to adapt in ways that go beyond portfolio adjustments.

R&D is the most apparent area. Novel precision medicine requires different scientific capabilities and a higher tolerance for complexity than traditional drug development. The probability of producing a genuinely differentiated therapy is higher, but so is the technical and regulatory difficulty. Early-stage innovation now predominantly originates in biotechs and academic spinouts. Large companies have become heavily dependent on external sourcing, with partnerships shifting from supplementary tools to the core of pipeline strategy. Increasingly, large pharma internalises assets after proof-of-concept and completes late-stage development in-house. Managing this dual model of simultaneously maintaining internal scientific capability and managing a high volume of external transactions is genuinely difficult.

Commercial models are being rebuilt in parallel. Large sales forces are giving way to smaller, dynamic teams in specialised centres. Patient support ecosystems require new operational capabilities and closer integration between commercial and medical functions.

Pricing and market access have become strategic disciplines. Health technology assessments leading to value-based agreements and outcomes-linked reimbursement require dedicated capabilities that simply did not exist in the legacy model. Aligning market access to the clinical trial data is commercially critical but often underinvested in relative to R&D spend.

We are already seeing movement in the hierarchy of the top twenty companies, with some incumbents falling out of that ranking entirely. Top fifty players are making ambitious moves to break into this coveted arena. Companies most at risk in the coming year are those who lack organisational agility to reach conviction early. It seems clear that by the end of this decade there will be a clear chasm between those willing to make bold decisions and those still discussing in the 5th layer of committee. The window to make that transition is narrowing.

The Next Decade in Pharma

Specialty pharma's share of the total pharmaceutical ecosystem will continue to grow, and the boundaries between who develops, commercialises, and finances these assets will keep shifting. Biotechs are demonstrating real commercial ambition. PE-backed platforms increasingly resemble mid-tier biopharma companies. Mid-tier pharma is taking risks on sizeable M&A to move up. Large pharma, meanwhile, behaves more like a portfolio manager of externally sourced risk than a vertically integrated developer. These distinctions are eroding, and the industry's self-image will need to catch up.

Yet even as these boundaries blur, each capital provider retains a distinct portfolio logic shaped by its cost of capital and the returns it must generate. VC holds multiple “shots on goal” through small stakes across many biotechs. Large pharma remains the custodian of blockbusters at various stages of their growth and maturity, deploying the capital and scale that position requires. PE-backed platforms grow through the aggregation of smaller assets, with their sponsors applying the same portfolio discipline that has served them across their broader funds.

The structural value this model has created extends beyond individual products. Specialty pharma has built a genuine commercialisation capability for assets that would otherwise remain underdeveloped, added liquidity options for investors and biotechs beyond the increasingly volatile IPO market, and developed a generation of specialists whose expertise in rare disease, market access, and launch execution represents a durable asset for the broader industry. Many of these professionals will cycle back into earlier-stage development, bringing commercial instinct into organisations that have historically lacked it.

There is also value for patients. The net effect has been more options in previously neglected disease areas, but also greater exposure to the pricing and access tensions that follow when commercial logic and clinical need are not perfectly aligned.

That scrutiny will only intensify. Demands for real-world evidence and outcomes-based arrangements will separate companies with sustained clinical value from those relying on trial data alone. The winners will be those who built the right relationships, and the right evidence base before the negotiation began.

Specialty pharma is no longer a fringe player in the ecosystem. It has become the dominant logic through which pharmaceutical value is created, competed for, and financed. The question is not whether to engage with that reality, but whether incumbent companies are moving fast enough, and with enough conviction, to compete within it.

--PFAm Issue 08--